INTRODUCTION
Although the current therapeutic strategy during acute myocardial infarction is to re-establish coronary blood flow by angioplasty, thrombolysis or cardiac surgery, the associated morbidity and mortality remain important and therefore require additional cardioprotection.
For many years, different approaches such as early and delayed preconditioning ( , ), pharmacological cardioprotection ( ) or more 1 2 3 -6 recently postconditioning, , brief interruptions of reperfusion with short episodes of myocardial ischemia ( ) have been extensively i.e. 7 investigated in this regard. Interestingly, clinical studies have demonstrated the benefit of ischemic postconditioning in patients with acute myocardial infarction ( ). However, the clinical translation of almost all these strategies is limited by the schedule of treatment as 8 -10 they must be applied either before the onset of ischemia or within the very first minutes of reperfusion ( ) and also by the fact that 11 -13 postconditioning is restricted to patients who are undergoing percutaneous coronary intervention. Therefore, the development of other cardioprotective strategies still remains a major challenge.
Cell death after ischemia-reperfusion occurs at least by necrosis and apoptosis. Apoptosis is a programmed cell death controlled by the death receptor, the mitochondrial pathways through caspase activation and also endogenous regulators of apoptotic cell death. In this setting, XIAP (X chromosome-linked Inhibitor of Apoptosis) is a major inhibitor of apoptosis in cardiomyocyte ( ) and ischemia or 14
Accordingly, the aim of the present study was to examine whether the C-terminal part of XIAP (BIR3 and RING domains) fused to the protein transduction domain (PTD) of the TAT-fusion system (HIV1 transactivator of transcription), , PTD-BIR3/RING, could protect i.e. the myocardium against infarction. Fusion of BIR3/RING domains with TAT confers to this aminoacidic sequence the ability to cross cell membranes with a great efficacy ( ), thereby decreasing the amount of protein needed for biological efficacy. We hypothesized that a 22 beneficial effect could be observed when PTD-BIR3/RING is administered before but also during reperfusion, by pharmacologically mimicking the effects of XIAP. In addition, we also investigated several proteins that play important roles in the apoptotic transduction signaling along with caspase activities.
METHODS
The experiments were performed in accordance with the official regulations of the French Ministry of Agriculture. The authors have been granted a license from the institutional office Pr fecture du Val de Marne (France) to conduct animal research (n A 94-028-245).
" é "°G
eneration, production and purification of PTD-BIR3/RING
A construct encoding the BIR3/RING domains of XIAP was amplified from the cDNA of the entire reading frame of rat XIAP and purified fragments were cloned into the I RI sites of the pTAT-HA vector ( ). The final cDNA encoded a protein comprising a Xho /Eco 23 6-histidine residues tag, the PTD sequence of TAT, a hemagglutinin (HA) tag and BIR3/RING sequences. Plasmids, , the i.e.
PTD-BIR3/RING and PTD-HA alone were expressed in the strain BL21(DE3) pLysS (Stratagene, La Jolla, CA, USA) as E. coli previously described ( ). Protein production was induced by addition of 500 M isopropyl 1-thio--D-galactoside. Proteins were 23 μ β extracted in 8M urea HEPES buffer and were purified using a Ni-NTA superflow agarose column (Qiagen, Hilden, Germany). Salt was removed using dialysis (Pierce Biotechnology Inc, Rockford, IL, USA) and proteins were collected in a solution containing phosphate buffered saline. The molecular weight of purified proteins was verified by Coomassie blue staining of electrophoresis gels.
Animal model of myocardial infarction
Male C57BL6/J mice (6 8 weeks) were anesthetized by intraperitoneal injection of pentobarbital sodium (50 mg/kg), intubated and -ventilated mechanically. The body temperature was measured using a rectal probe and was maintained at 37 C with a blanket connected to°a n homeothermic regulator (Homeo-blanket system 50-7221F, Harvard Apparatus, Les Ulis, France). A small catheter was inserted into a jugular vein for administration of the treatment and a thoracotomy was performed. A coronary artery occlusion and reperfusion was achieved with an 8-0 Prolene thread placed around the left coronary artery as previously described ( ). Myocardial ischemia was 24
confirmed by ST segment deviation of the electrocardiogram and the occurrence of regional cyanosis. Reperfusion was confirmed by visualisation of hyperemic response and the chest was closed in layers.
Experimental protocol
The experimental protocols are shown in . To determine the effects of PTD-BIR3/RING on myocardial infarct size, mice figure 1 underwent 30 min of coronary artery occlusion followed by 24 h of reperfusion. In these experiments, PTD-BIR3/RING (0.8 g/g) was μ injected intravenously either 5 min before ischemia as well as 5 min before and 30 min after the onset of reperfusion. The dose of 0.8 g/g μ was chosen on the basis of preliminary experiments investigating the infarct-limiting effects of increasing doses of PTD-BIR3/RING. The control groups were treated with vehicle (phosphate buffer saline) 5 min before ischemia, 5 min before and 30 min after the onset of reperfusion. Although it would have been more appropriate to use PTD-HA in the control mice, it is unlikely that the use of phosphate buffer saline represents an experimental biais as we verified that administration of PTD-HA (1 mg/ml and 0.8 g/g) alone at 30 min of μ reperfusion did not elicit proper effects on myocardial infarct size (40 4 , n 6 41 3 , n 9 for PTD-HA and phosphate buffer ± % = vs ± % = saline-treated mice, respectively).
Assessment of infarct size
At the end of the 24 h reperfusion period, the coronary artery was reoccluded at the previous site of occlusion. The area at risk was identified by negative Evan s blue dye staining and the infarct area was identified by triphenyltetrazolium chloride (TTC) negative ' staining. The area at risk was expressed as a percentage of the left ventricle weight. The infarcted area was expressed as percentages of the area at risk.
Histology
Briefly, formalin-fixed slices of infarcted hearts were embedded in paraffin for histological analysis. Five micrometers-thick sections were cut from each paraffin block and stained with H&E (Hematoxylin&Eosin).
Caspase activity assay
PTD-BIR3/RING and cardioprotection J Mol Cell Cardiol . Author manuscript Page / 3 10 In these experiments, PTD-BIR3/RING (0.8 g/g) was administered at 30 min of reperfusion and proteins were extracted from left μ ventricles after 1 h, 3 h and 24 h of reperfusion and assayed for caspase activity ( ). Extraction was also performed in 3 additional figure 1 mice that did not undergo ischemia-reperfusion. Tissues were homogenized in cold buffer (25mM HEPES pH 7.5, 5mM MgCl , 2mM 2 EDTA, 0.1 Triton X100, 2mM dithiothreitol, 1mM PMSF, 5 l/ml protease cocktail inhibitor P8849, Sigma-Aldrich, St Louis, MO, % μ USA). Homogenates were centrifuged and supernatants were collected. Proteins (50 g) were incubated in caspase assay buffer (50mM μ HEPES pH 7.4, 100mM NaCl, 1mM EDTA, 10mM dithiothreitol). Enzymatic reaction was started by addition of 0.2mM of the fluorogenic substrates ac-DEVD-AFC, ac-IETD-AFC, ac-LEHD-AFC (Biomol Research Laboratories, Hambourg, Germany) to caspase-3, caspase-8 and caspase-9, respectively. Fluorescent arbitrary units were converted into moles of AFC/h/mg protein using a μ standard curve of free AFC (Sigma-Aldrich, St Louis, MO, USA).
Western blot analysis
In these experiments, PTD-BIR3/RING (0.8 g/g) was administered at 30 min of reperfusion and proteins were extracted from left μ ventricles after 1 h reperfusion ( ). Myocardial samples were placed in medium containing 220mM Mannitol, 70mM Sucrose, figure 1 10mM HEPES, 1mM EGTA, 1mM PMSF, 5mM NaF, 1mM Na VO , 1mM Na Glycerol 2-phosphate, 5 l/ml protease inhibitor cocktail 3 4 2 μ (Sigma-Aldrich, St Louis, MO, USA), pH 7.4 at 4 C. The tissue was minced with scissors and homogenized on ice using a Teflon Potter°h omogenizer. The homogenate was centrifuged at 1000 for 5 min to remove cellular debris and nuclei. The supernatant was centrifuged g for 10 min at 10 000 to obtain the mitochondrial pellet. The latter was washed with the same medium and centrifuged at 10 000 for 10 g g min. The resulting mitochondrial pellet was resuspended with medium, frozen and thawed several times, and finally sonicated to extract the mitochondrial content. The 10 000 supernatant was centrifuged at 17 600 for 30 min. The resulting supernatant was the cytosolic g g fraction.
order to check for the absence of mitochondrial contamination of the cytosolic fraction, we verified the absence of citrate In synthase activity in the cytosolic samples.
Proteins were separated on 10 15 SDS-polyacrylamide gels using 40 80 g proteins per lane and transferred onto PVDF membranes 
Statistical analysis
All values are expressed as mean SEM for the number of samples indicated in the legends of figures. Comparisons between groups ± were assessed using ANOVA followed if necessary by Student s -test. Statistical significance was defined as a value of p<0.05. ' t
RESULTS

Effect of PTD-BIR3/RING on myocardial infarct size
As shown in , animal body weights and sizes of area at risk were similar among groups. As illustrated in ,  table 1  figure 2 PTD-BIR3/RING significantly reduced infarct size as compared to Control when administered 5 min before and 30 min after the onset of reperfusion (23 2 41 4 and 27 4 41 3 , respectively). Similar reduction in infarct size was observed when PTD-BIR3/RING ± % vs ± % ± % vs ± % was administered prior to ischemia (28 1 44 3 ). ± % vs ± %
Histology
In contrast with the major difference in infarct size between the two groups, histological analysis only revealed moderate different patterns of lesions within the infarct as shown in . In control mice, the main focus of infarction demonstrated a homogenous figure 3 pattern of cell death whereas in PTD-BIR3/RING treated mice, it was less homogenous and made of patchy foci of cell death.
Caspase activities
PTD-BIR3/RING and cardioprotection J Mol Cell Cardiol . Author manuscript Page / 4 10 In control mice, caspase-3, caspase-8 and caspase-9 activities were increased at 3 h of reperfusion as illustrated in . When figure 4 PTD-BIR3/RING was administered at 30 min of reperfusion, these increases were significantly blunted by PTD-BIR3/RING. After 24 h of reperfusion, all caspase activities were similar in the PTD-BIR-3/RING and control mice and these values were similar to those observed in mice that did not suffer ischemia-reperfusion (61 14, 69 7 and 7 1 M AFC/h/mg protein for caspase-3, -8 and -9, respectively).
Western blot analysis
As illustrated in , the phosphorylated Bad/Bad ratio was significantly increased in PTD-BIR3/RING treated mice ( 342 ) as figure 5 + % compared to Control. Concomitantly with inhibition of caspase-8 activity, we observed that the ratio of truncated Bid to total Bid was significantly reduced by PTD-BIR3/RING ( 41 ). In addition, as several pro-apoptotic proteins are known to translocate between the − % cytosol and the mitochondria, we analysed their subcellular location. Analysis of the cytosolic and mitochondrial fractions revealed that PTD-BIR3/RING significantly increased the Bax cytosolic to mitochondrial ratio as compared to Control. Finally, Smac/DIABLO cytosolic to mitochondrial ratios were similar between the two groups.
DISCUSSION
The present study demonstrates that the administration of BIR3/RING using the protein transduction domain (PTD) of the TAT-fusion system, , PTD-BIR3/RING up to 30 min during reperfusion significantly reduces myocardial infarct size in mice subjected to 30 min i.e. coronary artery occlusion. The novel finding is that the previously ischemic myocardium can be salvaged by pharmacologically mimicking the effects of XIAP during reperfusion. This is consistent with a previous report demonstrating that overexpression of the endogenous inhibitor IAP-2 significantly reduces myocardial infarct size and apoptosis ( ). The beneficial effect observed in our study was achieved 25 through inhibiting caspase-mediated cell death pathways. Besides inhibition of caspase-3 and -9, PTD-BIR3/RING also blunted the increase in caspase-8 activity. This was associated with the reduction of ischemia-induced truncation of Bid, a target of caspase-8, and
inactivation of key players of the apoptotic mitochondrial pathway such as the Bcl-2 family members Bax and Bad. Interestingly, PTD-BIR3/RING administered prior to ischemia or reperfusion did not afford a higher degree of protection than when administered at reperfusion suggesting that the cardioprotective effect of PTD-BIR3/RING is mainly related due to the interruption of deleterious signaling pathways that are activated during reperfusion.
Among numerous proteins that are known to regulate caspase activity, XIAP is the most potent inhibitor of apoptosis ( ). The PTD 26
peptide of the HIV1-TAT can enter into the cells efficiently when added exogenously and allows cellular delivery of macromolecules. In the present study, PTD-BIR3/RING had kept its main biological activity as its administration abolished the increases in caspase-3 and caspase-9 activities during reperfusion. More importantly, it has been demonstrated, using purified recombinant proteins, that the BIR3 domain is the minimal region of XIAP needed for potent caspase-9 inhibition ( ) and that the RING domain of XIAP is essential for 17 destruction of caspase-3 through the proteasome ( , ). Caspase-9 is an initiator caspase that is in the first wave of activation when 18 21 apoptosis is triggered. Caspase-3 is activated through the action of initiator caspases and its activation results in irreversible cell damage and death ( ). Histological analysis revealed differential tissular aspects as, in contrast to control mice, the main focus of infarct in the 27 PTD-BIR3/RING treated mice was less homogeneous suggesting patchy areas of salvaged tissues. It should also be considered that Smac/DIABLO is released by the mitochondria into the cytosol where it binds to IAPs, displacing caspases and thus enhancing the apoptotic signal ( ). In our experimental conditions, we observed that the cytosolic to mitochondrial ratio of Smac/DIABLO was 28 unchanged in PTD-BIR3/RING treated mice. We cannot exclude that part of PTD-BIR3/RING was inhibited by Smac/DIABLO.
Nevertheless, the effects observed in PTD-BIR3/RING treated animals indicate that the amount of administered PTD-BIR3/RING override the endogenous inhibitory effect of Smac/DIABLO.
We also demonstrated for the first time that PTD-BIR3/RING inhibits caspase-8 activity. This result is of great importance as caspase-8 is at crossroads between the extrinsic and intrinsic apoptosis pathways ( ) and plays multiple roles in apoptosis ( ). Besides 27 29 being an initiator caspase of the death-receptors pathway, caspase-8 exhibits a direct protease activity in the nucleus and plays an amplificatory role of the mitochondrial apoptotic pathway by cleavage and activation of the Bcl-2-related pro-apoptotic molecule Bid.
Truncated Bid activates another member of the Bcl-2 family, Bax, which translocates into the outer mitochondrial membrane and participates to the pore formation. The resulting release of apoptogenic factors activates effector caspases. Consistent with its protective effect, PTD-BIR3/RING induced a significant decrease in truncated Bid and reduced the translocation of Bax from the cytosol to the mitochondria as demonstrated by the reduction in Bax cytosolic to mitochondrial ratio. PTD-BIR3/TING was also responsible for an increase in the phosphorylation of Bad favouring its cytosolic sequestration.
Although we did not specifically investigate the mechanisms of caspase-8 inhibition by PTD-BIR3/RING, some hypotheses can be raised. CARPs (caspase-8 and -10 associated RING proteins) represent a family of anti-apoptotic proteins that specifically bind to and regulate DED (death effector domain) caspases such as caspase-8. Their RING domain possesses a high homology with the IAP family and exhibits a E3 ligase activity which may contribute to the ubiquitin-mediated proteolysis of DED caspases ( ). It has also beenthat inhibition of caspase-8 activity by PTD-BIR3/RING may involve the E3 ubiquitin ligase activity of its RING domain or an indirect inhibition through caspase-3 inhibition. However, investigation of these issues was beyond the scope of this study.
It is also important to emphasize that the beneficial effects of PTD-BIR3/RING were still observed when administered up to 30 min after the onset of reperfusion. To date, the so-called postconditioning or the administration of pharmacological agents have to be started within the very first minutes of reperfusion to be efficient. Indeed, starting administration of the adenosine agonist agent AMP579 after 10 min of reperfusion or postconditioning after the first minutes of reperfusion is too late ( , ). Such delayed cardioprotective effect of 11 12 PTD-BIR3/RING is rather similar to that reported with other pharmacological strategies ( , ). Finally, previous studies have also 32 33 reported the beneficial effects of several caspase inhibitors but the administration of the blockers was started before the onset of reperfusion ( ). 34 -37 In conclusion, this study demonstrates that the administration of PTD-BIR3/RING reduces myocardial infarct size even when administered during reperfusion. PTD-BIR3/RING exerts its cardioprotective effect through the interruption of caspase activation by pharmacologically mimicking endogenous XIAP.
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Figure 2
Individual and averaged values of infarct size expressed as percentage of the area at risk (AAR) measured at 24 h of coronary artery reperfusion (CAR) after 30 min coronary artery occlusion (CAO) in Control (C) and PTD-BIR3/RING-treated mice (BIR, 0.8 g/g). , p<0.05 μ * corresponding Control. vs 
Figure 5
Representative Western blots showing that PTD-BIR3/RING (BIR, shaded bars) administered at 30 min of reperfusion induced significant increase of phosphorylated Bad/Bad, Bax cytosolic to mitochondrial ratio as well as reduction in Bid truncation as compared to Control (C, open bars). Smac/DIABLO cytosolic to mitochondrial ratio was similar between PTD-BIR3/RING and Control. , p< 0.05 corresponding 
